Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel

Explore the latest updates, including expert interviews, features, podcasts and e-learning

The Multiple Myeloma Channel on VJHemOnc receives independent medical education support from Johnson & Johnson, Takeda, BMS, Amgen, Oncopeptides AB, Menarini, Stemline Therapeutics and Legend Biotech. These supporters have no influence over the production of the content.

Welcome to The Multiple Myeloma Channel

In association with our world-leading Editorial Board, VJHemOnc brings you the latest updates in multiple myeloma, directly from the experts. As well as video interviews, you can listen to our podcasts, dive into a roundtable discussion and e-learning, or read our feature articles.

The Myeloma Channel brings you the latest advances in therapy, including monoclonal antibodies, CAR-T cells, bispecific antibodies, as well as up-to-date data and guidance on optimizing treatment combinations, sequencing and managing difficult-to-treat patient groups. The Myeloma Channel also delves into the latest research on the understanding of precursor state progression, such as monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma to active disease, the tumor microenvironment, and more.


EHA 2024
ASCO 2024
COMy 2024
AACR 2024
CAR-T Meeting 2024
ASH 2023


CAR-T & Cellular Therapy
Real-World Data
Trial Updates